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OBJECTIVES This study assessed left ventricular myocardial perfusion and sympathetic innervation and
function in hypertrophied and nonhypertrophied myocardial regions of patients with
hypertrophic cardiomyopathy (HCM).
BACKGROUND Patients with HCM often have clinical findings consistent with increased cardiac sympathetic
outflow. Little is known about the status of sympathetic innervation specifically in hypertro-
phic regions.
METHODS We conducted positron emission tomographic (PET) scanning using the perfusion imaging
agent 13N-ammonia (13NH3) and the sympathoneuronal imaging agent 6-[
18F]-
fluorodopamine (18F-FDA) in 8 patients with HCM and 15 normal volunteers. Positron
emission tomographic data corrected for attenuation and the partial volume effect were
analyzed using the region-of-interest technique.
RESULTS Myocardial 13NH3-derived radioactivity was similar in hypertrophied and nonhypertrophied
regions of patients with HCM and in normal volunteers. At all time points, the 18F:13N ratio
was lower in hypertrophied than in nonhypertrophied regions of HCM patients and in the
septum of normal volunteers (p 5 0.001). Trends in 18F-FDA-derived radioactivity over time
were normal in both hypertrophied and nonhypertrophied myocardium.
CONCLUSIONS The results are consistent with decreased neuronal uptake of catecholamines in hypertrophied
but not in nonhypertrophied myocardium of patients with HCM. Other aspects of cardiac
sympathoneural function seem normal. Decreased neuronal uptake could reflect local relative
hypoinnervation, decreased numbers of neuronal uptake sites, or metabolic limitations on cell
membrane transport. By enhancing norepinephrine delivery to adrenoceptors for a given
amount of sympathetic nerve traffic, decreased neuronal uptake can explain major clinical
features of HCM. (J Am Coll Cardiol 2000;35:1867–73) © 2000 by the American College
of Cardiology
Hypertrophic cardiomyopathy (HCM) is a genetic disease
inherited as an autosomal dominant trait and characterized
by left ventricular hypertrophy in the absence of other causes
for increased cardiac mass (1–5). The disease results from
missense mutations of genes encoding sarcomeric proteins
such as beta-myosin heavy chain, essential and regulatory
light chain of myosin, alpha-tropomyosin, cardiac troponin
T or I, or cardiac myosin binding protein C (6–11).
Clinical features of HCM, such as chest pain, progression
of left ventricular hypertrophy, myocardial hypercontractil-
ity, propensity to ventricular arrhythmias and sudden death,
and the beneficial effect of beta-adrenoceptor blockers,
suggest increased cardiac sympathetic outflow and, conse-
quently, increased delivery of the sympathetic neurotrans-
mitter, norepinephrine, to myocardial adrenoceptors (3–
5,12,13). Norepinephrine not only elicits vasoconstriction,
increases myocardial oxygen consumption, and increases the
rate of spontaneous depolarization of myocardial cells
acutely, but also acts as a hypertrophic factor in cardiovas-
cular smooth muscle cells (14–17).
Any of several abnormalities of cardiac sympathetic in-
nervation or function can increase norepinephrine delivery
to adrenoceptors. The most straightforward is an increase in
the rate of local sympathetic nerve traffic, which increases
release of norepinephrine from the nerve terminals. Al-
though a previous study reported an increased appearance
rate of norepinephrine in plasma in the great cardiac vein
(cardiac norepinephrine spillover) in patients with HCM
(18), the increase was relatively small, and, as noted below,
increased cardiac sympathetic traffic alone cannot account
for some other neurochemical findings.
Decreased neuronal reuptake of norepinephrine (Uptake-
1), the main means for terminating the actions of norepi-
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nephrine in the human heart (19), also increases delivery of
norepinephrine to adrenoceptors (20). Consistent with this
mechanism, patients with HCM have a decreased fractional
extraction of 3H-norepinephrine and a decreased arterio-
venous increment in plasma levels of dihydroxyphenylglycol,
the main neuronal metabolite of norepinephrine, compared
with control patients (18).
Studies of cardiac kinetics of 3H-norepinephrine and its
metabolites cannot provide information about possible ab-
normalities of sympathetic innervation or function specifi-
cally in hypertrophied regions. Investigators (21,22) have
reported decreased 123I-meta-iodozylganidine-derived
(123I-MIBG-derived) radioactivity in the hypertrophied
regions of patients with HCM, and Schafers et al. (23)
reported reduced 11C-hydroxyephedrine-derived radioactiv-
ity. These findings are consistent with locally decreased
Uptake-1 activity; however, other abnormalities of cardiac
sympathetic function can produce the same results.
Positron emission tomographic (PET) scanning after
injection of 6-[18F]-fluorodopamine (18F-FDA), a newly
developed catecholamine that acts as a false adrenergic
neurotransmitter (Fig. 1), can visualize cardiac sympathetic
innervation and function (24–29). Sympathetic nerve ter-
minals rapidly take up circulating 18F-FDA and sequester it
extensively in axoplasmic vesicles (24,30). The heart:blood
ratio of 18F-FDA is 2:1 at 5 min and 9:1 at 180 min after
injection (27).
Alterations in specific aspects of sympathetic neuroeffec-
tor function, including Uptake-1 activity, vesicular transport
and storage of monoamines, oxidative deamination, and
postganglionic sympathetic nerve traffic, produce character-
istic changes in curves relating 18F-FDA–derived myocar-
dial radioactivity to time (time-activity curves, TACs).
Treatment with desipramine, which blocks Uptake-1, or
6-hydroxydopamine, which destroys sympathetic nerve ter-
minals, decreases cardiac uptake of 18F-FDA (25,27,31).
Reserpine, which blocks vesicular transport of axoplasmic
monoamines, does not affect myocardial uptake of 18F-FDA
but markedly decreases retention of 18F-FDA (25). In-
creased sympathetic activity, induced by exercise or sublin-
gual nitroglycerin, increases the rate of loss of 18F-FDA–
derived myocardial radioactivity (32), whereas ganglion
blockade with trimethaphan prolongs the loss of 18F-FDA–
derived myocardial radioactivity (25,27).
This study used 18F-FDA PET scanning to evaluate
whether patients with HCM have alterations in sympathetic
innervation or function in the hypertrophied regions that
might predispose to a hyperadrenergic state. We also used
the perfusion imaging agent 13N-ammonia (13NH3) (33) to
adjust 18F-FDA concentrations for possible regional differ-
ences in delivery by the bloodstream (18F:13N ratio).
METHODS
Subjects. Both 18F-FDA and 13NH3 were administered
and thoracic PET scanning performed in 15 healthy adult
volunteers (11 men and 4 women, aged 54 6 22 years) and
8 patients with HCM (6 men and 2 women, aged 42 6 18
years). All the volunteers had normal medical history,
physical examination, electrocardiogram (ECG), and labo-
ratory (blood and urine) tests. Of the 8 HCM patients,
asymmetric septal hypertrophy was present in 5 (2 with
hypertrophy of the apex as well), whereas hypertrophy was
more diffuse in 3 patients, so that there were 8 hypertro-
phied and 5 nonhypertrophied regions. Caffeine-containing
beverages, cigarettes, and alcohol were proscribed for at least
24 h before PET scanning.
The study protocol was approved by the Clinical Re-
search Subpanel of the National Institute of Neurological
Disorders and Stroke (NINDS). Each subject gave written
informed consent.
PET scanning. Three-dimensional PET studies were per-
formed on an Advance™ whole-body scanner (General
Electric, Milwaukee, Wisconsin). An 8-min transmission
scan, using rotating 68Ge/68Ga pin sources, was obtained for
Abbreviations and Acronyms
13NH3 5
13N-ammonia
18F-FDA 5 6-[18F]-fluorodopamine
HCM 5 hypertrophic cardiomyopathy
PET 5 positron emission tomography
ROI 5 region of interest
Figure 1. The structure (A) and fate of 6-[18F]-fluorodopamine
(B).
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attenuation correction and for confirming the location of
the heart, before the 13NH3 and
18F-FDA PET scans.
Immediately after the first transmission scan, myocardial
perfusion was assessed by PET imaging (35 contiguous
transaxial slices 4.25 mm apart) for 20 min after a 1-min IV
infusion of 5 mCi of 13NH3.
For sympathoneuronal imaging, after the second trans-
mission scan, PET images (35 contiguous transaxial slices
4.25 mm apart) were acquired after IV infusion of 18F-FDA
(synthesized as described previously) (27) at a constant rate
for 3 min after, beginning at least 1 h after 13NH3
administration. A series of PET scans (5 frames 3 1 min,
5 3 5 min, 4 3 15 min, and 3 3 30 min, total 3 h) was
acquired.
Data analysis. The 18F-FDA data were reconstructed after
correction for attenuation and for physical decay of 18F.
Cardiac images were analyzed as described previously (27).
Briefly, circular regions of interest (ROIs) approximately
half the ventricular wall thickness were placed on images of
the septum, lateral wall, and left ventricular chamber using
time-averaged pictures of a single slice. Left ventricular
radioactivity was averaged from two ROIs each in the left
ventricular free wall and septum. Time-activity curves re-
lating myocardial radioactivity with time were constructed
from the dynamic PET data and compared between the
HCM and control groups.
Static 13NH3 PET images were reconstructed after anal-
ogous correction for attenuation and physical decay of 13N
and analyzed using the same ROI technique.
Radioactivity concentrations were standardized by cor-
recting for the dose of radioactive drug per unit body mass
of the subject and expressed as nCi z kg/cc z mCi.
Because infused 18F-FDA is delivered by the blood-
stream, the amount of 18F-FDA–derived radioactivity de-
pends on regional perfusion. To correct 18F-FDA–derived
radioactivity for regional perfusion, the ratio of 18F-FDA–
derived radioactivity to 13NH3-derived radioactivity (
18F:
13N) was calculated in the same ROIs.
Correction for partial volume effect. Because of asym-
metric septal hypertrophy, increased septal myocardial con-
centrations of 18F and 13N might reflect a partial volume
effect. To correct for this effect, thicknesses of the left
ventricualr free wall and septum were measured by echocar-
diography, and recovered coefficient functions for the GE
Advance™ PET scanner were calculated and applied by
blurring in-plane data with a two-dimensional Gaussian
filter (34,35).
Statistics. All data were expressed as means 6 SEM. The
HCM and normal volunteer groups were compared using
between–within analyses of variance (2-factor repeated-
measures analysis of variance [ANOVA]), the between
factor being diagnosis and the within factor being time
(StatView SE1Graphics™, Abacus Concepts, Berkeley,
California). A factorial ANOVA was used to assess effects
of blood flow and diagnostic group on myocardial 18F-
FDA–derived radioactivity.
Bi-exponential equations of best fit were calculated using
a “peeling” approach to describe the relationships between
myocardial radioactivity and time in each subject. The
equation for the mono-exponential line of best fit for the
late phase, including the y-intercept (yo) and apparent rate
constant (k), was determined for the last four scanning
intervals (midpoints 97.5 min to 165 min after administra-
tion of 18F-FDA; Cricket Software, Malvern, Pennsylva-
nia). Differences between the estimated and empirical values
were calculated and graphed, and the mono-exponential line
of best fit for the early phase was determined, beginning
with the peak value of 18F-FDA–derived radioactivity.
Values for yo and k for the early phase were than calculated.
Values for yo and k for
18F-FDA–derived radioactivity,
with and without adjustment for perfusion, were compared
to those in the normal volunteers, using independent-means
t-tests. Statistical significance was defined by a p value less
than 0.05.
RESULTS
After administration of 18F-FDA or 13NH3, the left ven-
tricular myocardium was visualized clearly in all subjects
(Fig. 2). The myocardial distribution of both tracers was
more heterogeneous in patients with HCM than in normal
volunteers.
Mean left ventricular myocardial radioactivity. Values
for time-averaged 13NH3-derived radioactivity in left ven-
tricular myocardium as a whole were similar in patients with
HCM (7137 6 506 nCi z kg/cc z mCi) and in normal
volunteers (7293.4 6 409 nCi z kg/cc z mCi; Fig. 3).
The mean concentration of 18F-FDA–derived radioac-
tivity in left ventricular myocardium increased to a peak at 5
to 8 min after initiation of the 3-min infusion in both
subject groups (8499 6 722 nCi z kg/cc z mCi in HCM
patients, 10,263 6 673 nCi z kg/cc z mCi in normal volun-
teers). The 18F-FDA–derived radioactivity thereafter de-
clined bi-exponentially. In both the early and late phases of
the decline, the groups did not differ in mean values for k or
yo (Table 1).
There was a significant time-dependent decline of 18F-
FDA–derived radioactivity (F 5 134.2, p 5 0.0001).
Patients with HCM had a lower mean ratio of 18F:13N than
did the normal volunteers (F 5 11.1, p 5 0.0039), and the
trend in 18F:13N differed significantly between the groups
(F 5 2.39, p 5 0.0085; Fig. 4, upper part). The peak value
also occurred significantly earlier in the HCM patients
(5.1 min vs. 8.0 min; Fig. 4, lower part).
Hypertrophied versus nonhypertrophied regions in pa-
tients with HCM. After correction for the partial volume
effect, mean 13NH3-derived radioactivity in hypertrophied
regions did not differ from that in nonhypertrophied regions
(Fig. 3).
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Peak 18F-FDA– derived radioactivity (9457 6
1074 nCi z kg/cc z mCi in hypertrophied regions, 9436 6
1084 nCi z kg/cc z mCi in nonhypertrophied regions) and
mean values for k or yo (Table 1) did not differ between
hypertrophied and nonhypertrophied regions in patients with
HCM.
Hypertrophied regions in patients with HCM versus
controls. After correction for the partial volume effect,
13NH3-derived radioactivity in hypertrophied regions of pa-
tients with HCM (7767 6 680 nCi z kg/cc z mCi) did not
differ significantly from that in the left ventricular myocardium
of normal volunteers (7428 6 413 nCi z kg/cc z mCi; Fig. 3).
Neither mean peak 18F-FDA–derived radioactivity nor
13NH3-derived radioactivity (6694 6 425 nCi z kg/
cc z mCi) in nonhypertrophied regions of patients with
HCM differed from the corresponding values in normal
volunteers.
Perfusion-adjusted 18F-FDA– derived radioactivity. In
the hypertrophic regions of patients with HCM, the mean
ratio of 18F:13N was significantly less than that in normal
volunteers (F 5 15.7, p 5 0.001). The 18F-FDA–derived
radioactivity declined in a time-dependent manner (F 5
137.4, p 5 0.0001), and the groups differed significantly in
the trends of 18F:13N (F 5 3.20, p 5 0.0005). The ratio of
peak 18F-FDA–derived radioactivity to 13NH3-derived ra-
dioactivity was also significantly lower in hypertrophied
than in nonhypertrophied regions of HCM patients (t 5
2.13) or in normal volunteers (t 5 3.87, p 5 0.0005; Fig. 4).
Among the five patients with asymmetric septal hypertro-
phy, the mean ratio of septal 18F:13N was also significantly
less than that in normal volunteers (F 5 13.4, p 5 0.0023).
The 18F-FDA–derived radioactivity declined in a time-
dependent manner (F 5 115.8, p 5 0.0001), and the groups
differed significantly in the trends of 18F:13N (F 5 3.27, p 5
0.0005).
Figure 2. Thoracic positron emission tomographic scans depicting (left) myocardial 13N-ammonia–derived radioactivity, (middle)
6-[18F]-fluorodopamine–derived radioactivity, and (right) the ratio of 18F:13N in (top) a normal volunteer and (bottom) a patient with
hypertrophic cardiomyopathy, after IV injection of 5 mCi 13N-ammonia and then 1 mCi 6-[18F]-fluorodopamine. Sep 5 septum; Lat 5
lateral wall; Ap 5 apex; LV 5 left ventricle.
Figure 3. 13NH3-Derived radioactivity in patients with hypertro-
phic cardiomyopathy and normal volunteers. HCM 5 average
myocardial radioactivity of patients with hypertrophic cardiomy-
opathy (n 5 8); HY 5 radioactivity in hypertrophied regions of
patients with HCM (n 5 8); NH 5 radioactivity in nonhyper-
trophied regions of patients with HCM (n 5 5); NL 5 average
radioactivity in left ventricular myocardium of normal volunteers
(n 5 15); NF 5 radioactivity in left ventricular free wall of normal
volunteers (n 5 15); NS 5 radioactivity in septum of normal
volunteers (n 5 15).
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Peak 18F-FDA–derived radioactivity correlated positively
with 13NH3-derived radioactivity across subjects (Fig. 5).
For a given amount of 13NH3-derived radioactivity, patients
with HCM had lower values for peak 18F-FDA–derived
radioactivity in the hypertrophied than nonhypertrophied
regions (F 5 12.7, p 5 0.0044) and myocardium of normal
volunteers (F 5 16.2, p 5 0.0006). The relationship
between 18F-FDA– derived radioactivity and 13NH3-
derived radioactivity did not vary as a function of the
diagnostic group or hypertrophied status. For a given
amount of 13NH3-derived radioactivity, peak
18F-FDA–
derived radioactivity in nonhypertrophied regions of pa-
tients with HCM was similar to that in normal volunteers.
DISCUSSION
The main finding of the present study was in patients with
HCM, ratios of 18F-FDA–derived radioactivity to 13NH3-
derived radioactivity in hypertrophied regions were signifi-
cantly smaller than those in nonhypertrophied regions or in
left ventricular myocardium of normal volunteers. As ex-
plained below, these findings indicate decreased neuronal
uptake of 18F-FDA by cardiac sympathetic nerve terminals
for a given amount of delivery by blood perfusion in the
hypertrophied regions.
Figure 4. Mean values (6SEM) for the ratio of 18F:13N in septum
or average of left ventricular myocardium of normal volunteers
(n 5 15) and in hypertrophied (n 5 8) and nonhypertrophied
regions (n 5 5) of patients with hypertrophic cardiomyopathy,
after injection of 13N-ammonia and then 6-[18F]-fluorodopamine.
Figure 5. Relationship between peak 18F-FDA–derived radioac-
tivity and 13NH3-derived radioactivity in hypertrophied and non-
hypertrophied regions of 7 patients with HCM (another 1 outlier
deleted) and in left ventricular myocardium of 15 normal volun-
teers.
Table 1. Kinetic Parameters for 6-[18F]-Fluorodopamine–Derived Radioactivity in Normal Volunteers and in Patients With
Hypertrophic Cardiomyopathy
Parameter
Normal
Volunteers
HCM
Mean LV
Hypertrophied
Region
Nonhypertrophied
Region
yo Early 7146.44 6 432.32 6959.49 6 743.49 7361.33 6 944.81 6943.02 6 1325.70
yo Late 5944.78 6 616.09 4795.39 6 665.87 5176.43 6 563.19 4580.58 6 663.42
k Early 0.0465 6 0.0081 0.0427 6 0.0039 0.0418 6 0.0058 0.0525 6 0.0068
k Late 0.0041 6 0.0007 0.0053 6 0.0009 0.0055 6 0.0008 0.0050 6 0.0004
T1⁄2 early 14.91 16.24 16.58 13.20
T1⁄2 late 169.86 130.05 126.33 137.50
Mean values are expressed as 6 SEM. yo 5 y-intercept; nCi z kg/cc z mCi; k 5 apparent rate constant, min
21; T1⁄2 5 half time, min; HCM 5 hypertrophic cardiomyopathy;
LV 5 left ventricular myocardium.
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Cardiac sympathetic function in hypertrophied regions.
Shapes of curves relating myocardial 18F-FDA–derived
radioactivity with time in patients with HCM did not differ
from those in normal volunteers, even after adjustment for
perfusion. Thus, the decrease in perfusion-adjusted 18F-
FDA–derived radioactivity did not result from accelerated
loss of 18F-FDA–derived radioactivity after neuronal up-
take of the tracer, as would occur with decreased efficiency
of the vesicular monoamine transporter (25) or with in-
creased regional sympathetic nerve traffic (32).
The present results confirm and extend those from other
studies using different sympathoneural and perfusion imag-
ing agents, indicating decreased Uptake-1 activity in myo-
cardium of patients with HCM. Shimizu et al. (22) reported
reduced 123I-MIBG–derived radioactivity in hypertrophied
regions of patients with HCM who had a conduction
disturbance or decrease in or disappearance of a negative T
wave during 12 months of serial electrocardiography, com-
pared with patients who had an increase in or appearance of
a negative T wave; however, the study did not include a
control group and did not consider possible regional differ-
ences in perfusion.
In addition, Nakajima et al. (36) noted reduced 123I-
MIBG– derived radioactivity for a given amount of
201Tl uptake in hypertrophied regions of patients with
septal thicknesses exceeding 16 mm, compared to patients
with septal thicknesses less than 16 mm; this study also
did not include a control group. Scha¨fers et al. (23) found
a decreased cardiac volume of distribution of 11C-
hydroxyephedrine in patients with HCM compared with
values in control subjects, consistent with decreased neuro-
nal uptake; however, that study did not examine possible
regional localization of the abnormality within the myocar-
dium. Ungerer et al. (21) reported a close correlation
between 11C-hydroxephedrine uptake and tissue norepi-
nephrine content in cardiomyopathic human heart; how-
ever, the patients all had dilated, not hypertrophic, cardio-
myopathy.
Decreased 18F-FDA uptake in hypertrophied regions in
patients with HCM could reflect relative sympathetic hypo-
innervation, such as by “dilution” of nerve terminals by
hypertrophied myocardial cells and interstitial fibrosis (4).
Because myocardial uptake and retention of 18F-FDA
requires the energy-dependent Uptake-1 process (25), and
because patients with HCM can have impaired oxidative
and glucose metabolism in hypertrophied regions (37,38),
locally decreased uptake of 18F-FDA might also result from
local metabolic changes. Although decreased neuronal up-
take could also result from increased effective arteriovenous
shunting, related to decreased arteriolar density (39), this
would not have decreased the 18F:13N ratio.
Myocardial perfusion in hypertrophied regions. Avail-
able published reports about regional myocardial blood flow
and perfusion in patients with HCM have been remarkably
inconsistent. Investigators (36) reported increased regional
uptake of 201Tl in the hypertrophied septa of patients with
HCM. Camici et al. (40) found more 13NH3-derived
radioactivity in the hypertrophied septum than in the
nonhypertrophied free wall, although the difference from
corresponding values in control subjects was not significant.
In contrast, Ishiwata et al. (37) and Tadamura et al. (38)
reported reduced 11C-acetate–derived radioactivity, which
is a measure of myocardial perfusion (41), and Grover-
McKay et al. (34) and Nienaber et al. (42) reported reduced
13NH3-derived radioactivity in the hypertrophied regions.
Hypertrophied regions have normal uptake of 15O-water
(42–44).
Some of these differences may have arisen from lack of
correction for the partial volume effect in hypertrophied
myocardial regions. In the present study, after correction for
the partial volume effect, 13NH3-derived radioactivity in
hypertrophied regions was approximately normal.
Cardiac sympathetic innervation and myocardial perfu-
sion in nonhypertrophied regions. Both 18F-FDA–
derived and 13NH3-derived radioactivity levels were normal
in nonhypertrophied regions of patients with HCM, and
trends in perfusion-adjusted 18F-FDA–derived radioactiv-
ity were similar in patients with HCM and in normal
volunteers. These findings indicate normal postganglionic
nerve traffic to functionally intact sympathetic nerve termi-
nals in the nonhypertrophied regions.
In summary, decreased perfusion-adjusted 18F-FDA–
derived radioactivity appears to reflect decreased neuronal
uptake (Uptake-1) by sympathetic nerves in hypertrophied
but not in nonhypertrophied regions of patients with HCM.
Because of the importance of Uptake-1 for terminating the
actions of catecholamines in the human heart (19), de-
creased Uptake-1 activity would be expected to augment
delivery of locally released and circulating catecholamines to
adrenoceptors in the hypertrophied myocardium during
sympathetic or adrenomedullary activation. This in turn
could contribute to hypercontractility, susceptibility to ven-
tricular arrhythmias, reduced coronary vasodilator reserve,
and progressive hypertrophy in HCM.
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